Juliette Berger

614 total citations
28 papers, 425 citations indexed

About

Juliette Berger is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Juliette Berger has authored 28 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 8 papers in Genetics and 6 papers in Molecular Biology. Recurrent topics in Juliette Berger's work include Chronic Lymphocytic Leukemia Research (7 papers), Lysosomal Storage Disorders Research (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Juliette Berger is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Lysosomal Storage Disorders Research (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Juliette Berger collaborates with scholars based in France, Austria and United Kingdom. Juliette Berger's co-authors include Andreas Widschwendter, Martin Widschwendter, G. Daxenbichler, Elisabeth Müller‐Holzner, Christian Marth, Andrea Mayr, Marc Berger, Chantal Rapatel, Céline Bourgne and Nathalie Boiret‐Dupré and has published in prestigious journals such as Blood, Scientific Reports and Nutrients.

In The Last Decade

Juliette Berger

26 papers receiving 410 citations

Peers

Juliette Berger
Paul W. Fisher United States
Titus Sparna Germany
Mary R. Dusing United States
Rachel S. Salamon United States
I. L. O. Ponting United Kingdom
Katja Björklöf Switzerland
Juliette Berger
Citations per year, relative to Juliette Berger Juliette Berger (= 1×) peers Daniela Di Marcantonio

Countries citing papers authored by Juliette Berger

Since Specialization
Citations

This map shows the geographic impact of Juliette Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juliette Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juliette Berger more than expected).

Fields of papers citing papers by Juliette Berger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juliette Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juliette Berger. The network helps show where Juliette Berger may publish in the future.

Co-authorship network of co-authors of Juliette Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Juliette Berger. A scholar is included among the top collaborators of Juliette Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juliette Berger. Juliette Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berger, Marc, Céline Lesueur, Juliette Berger, et al.. (2024). Deciphering metabolic shifts in Gaucher disease type 1: a multi-omics study. Journal of Molecular Medicine. 103(2). 187–203. 2 indexed citations
2.
Mauhin, Wladimir, Javier I. Ottaviani, Olivier Lidove, et al.. (2024). Lysosphingolipid Quantitation in Plasma and Dried‐Blood Spots Using Targeted High‐Resolution Mass Spectrometry. Journal of Clinical Laboratory Analysis. 39(1). e25131–e25131.
3.
Bourgne, Céline, Chinmay Munje, Juliette Berger, et al.. (2022). The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia. Cancers. 14(19). 4695–4695. 3 indexed citations
4.
Gladine, Cécile, Bruno Pereira, Juliette Berger, et al.. (2021). Does iron overload in metabolic syndrome affect macrophage profile? A case control study. Journal of Trace Elements in Medicine and Biology. 67. 126786–126786. 5 indexed citations
5.
Berger, Juliette, Agnès Guerci, Pascale Cony‐Makhoul, et al.. (2021). Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34− and immature CD34+ cells. Scientific Reports. 11(1). 6187–6187.
6.
Tebani, Abdellah, Wladimir Mauhin, Lénaïg Abily-Donval, et al.. (2020). A Proteomics-Based Analysis Reveals Predictive Biological Patterns in Fabry Disease. Journal of Clinical Medicine. 9(5). 1325–1325. 32 indexed citations
7.
Raskovalova, Tatiana, Patrick Deegan, Pramod K. Mistry, et al.. (2020). Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data. Haematologica. 106(2). 437–445. 20 indexed citations
8.
Wauquier, Fabien, Stéphanie Krisa, Tristan Richard, et al.. (2019). Chondroprotective Properties of Human-Enriched Serum Following Polyphenol Extract Absorption: Results from an Exploratory Clinical Trial. Nutrients. 11(12). 3071–3071. 18 indexed citations
9.
Bourgne, Céline, Juliette Berger, Karin Tarte, et al.. (2014). The Chronic Lymphocytic Leukemia Clone Disrupts the Bone Marrow Microenvironment. Stem Cells and Development. 23(24). 2972–2982. 18 indexed citations
10.
Bourgne, Céline, Juliette Berger, Chantal Rapatel, et al.. (2014). Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk348) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML). Leukemia Research. 39(3). 329–334. 4 indexed citations
11.
Bourgne, Céline, Mahchid Bamdad, F. Libert, et al.. (2012). Measurement of imatinib uptake by flow cytometry. Cytometry Part A. 81A(11). 996–1004. 8 indexed citations
12.
Berger, Juliette, Séverine Lecourt, Valérie Vanneaux, et al.. (2010). Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease. British Journal of Haematology. 150(1). 93–101. 26 indexed citations
13.
Boiret‐Dupré, Nathalie, Stéphane Descamps, Chantal Rapatel, et al.. (2009). Effects of imiglucerase treatment on traumatic fracture and bone and blood abnormalities in a patient with previously untreated type 1 gaucher disease. Clinical Therapeutics. 31(12). 2900–2904. 1 indexed citations
14.
Richard, C., Véronique Maguer‐Satta, Juliette Berger, et al.. (2007). In Vitro Toxicity of Fludarabine on Normal Bone Marrow (BM) Progenitors Suggests Its Involvement in the Impairment of Hematopoietic Progenitor (HP) Mobilization.. Blood. 110(11). 1192–1192. 2 indexed citations
15.
Boiret, Nathalie, Chantal Rapatel, Stéphane Boisgard, et al.. (2003). CD34+CDw90(Thy-1)+ subset colocated with mesenchymal progenitors in human normal bone marrow hematon units is enriched in colony-forming unit megakaryocytes and long-term culture-initiating cells. Experimental Hematology. 31(12). 1275–1283. 19 indexed citations
16.
Charrier, Sabine, Nathalie Boiret, Marc Fouassier, et al.. (2002). Normal human bone marrow CD34+CD133+ cells contain primitive cells able to produce different categories of colony-forming unit megakaryocytes in vitro. Experimental Hematology. 30(9). 1051–1060. 18 indexed citations
17.
Boiret, Nathalie, Justyna Kanold, Marc Fouassier, et al.. (2000). CFU-Mk Content of Immunoselected CD34 + Peripheral Blood Progenitor Cells, Evaluated with an Adapted Serum-Free Methylcellulose Assay, Is Predictive of Platelet Lineage Reconstitution in Children with Solid Tumors. Journal of Hematotherapy & Stem Cell Research. 9(4). 525–534. 10 indexed citations
18.
Widschwendter, Martin, Juliette Berger, G. Daxenbichler, et al.. (1997). Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer.. PubMed. 57(19). 4158–61. 136 indexed citations
19.
Berger, Juliette, et al.. (1993). Acute jejunal ileus in intestinal lymphangiectasia. Journal of Molecular Medicine. 71(7). 568–71. 17 indexed citations
20.
Feldman, Stuart, et al.. (1974). In Vitro Assessment of In Vivo Absorption of Drug Complexes. Journal of Pharmaceutical Sciences. 63(3). 454–456. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026